Intravenous iron exposure and outcomes in patients on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2014, Pages 1837-1839

  Fishbane, Steven ^a   Mathew, Anna T ^a   Wanchoo, Rimda ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

BACTEREMIA; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; END STAGE RENAL DISEASE; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HEMODIALYSIS; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; IRON STORAGE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; SEPSIS; SURVIVAL; ADVERSE EFFECTS; CARDIOVASCULAR DISEASE; FEMALE; INFECTION; MALE; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFECTION; IRON; MALE; RENAL DIALYSIS;

EID: 84923918487     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09510914     Document Type: Editorial

References (20)

1. Gao W, Li X, Gao Z, Li H: Iron increases diabetes-induced kidney injury and oxidative stress in rats. Biol Trace Elem Res 160: 368–375, 2014.
2. Zager RA, Johnson AC, Hanson SY: Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65: 2108–2112, 2004.
3. Ganz T: Hepcidin and iron regulation, 10 years later. Blood 117: 4425–4433, 2011.
4. Hultén L, Gramatkovski E, Gleerup A, Hallberg L: Iron absorption from the whole diet. Relation to meal composition, iron requirements and iron stores. Eur J Clin Nutr 49: 794–808, 1995.
5. Winchester J F: Management of iron overload in dialysis patients. Semin Nephrol 6[Suppl 1]: 22–26, 1986.
6. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29: 319–333, 1997.
7. US Renal Data System: 2013 Atlas of CKD & DSRD. Available at: http://www.usrds.org/atlas.aspx. Accessed September 16, 2014.
8. The Dialysis Outcomes and Practice Patterns Study: DOPPS Practice Monitor: Most recent Trends in US Hemodialysis Practice. Available at: http://www.dopps.org/DPM/DPM_highlights.pdf. Accessed September 16, 2014.
9. Singh N, Agarwal A K: Pumping iron: Revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 77: 188–194, 2012.
10. Coyne D W, Kapoian T, Suki W, Singh A K, Moran J E, Dahl N V, Rizkala A R; DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J AmSoc Nephrol 18: 975–984, 2007.
11. Feldman H I, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623–1632, 2004.
12. Kalantar-Zadeh K, Regidor D L, McAllister C J, Michael B, Warnock D G: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070–3080, 2005.
13. Kuo K-L, Hung S-C, Lin Y-P, Tang C-F, Lee T-S, Lin C-P, Tarng D C: Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 7: e50295, 2012.
14. Miskulin DC, Tangri N, Bandeen-Roche K, Zou J, McDermott A, Meyer K B, Ephraim PL, Michels WM, Jaar BG, Crews D C, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE: Intravenous iron exposure and mortality in hemodialysis patients. Clin J Am Soc Nephrol 9: 1930–1939, 2014.
15. Neilands JB: Siderophores: Structure and function ofmicrobial iron transport compounds. J Biol Chem270: 26723–26726, 1995.
16. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38: 1090–1094, 2004.
17. Brookhart M A, Freburger J K, Ellis A R, Wang L, Winkelmayer W C, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J AmSoc Nephrol 24: 1151–1158, 2013.
18. Litton E, Xiao J, Ho KM: Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 347: f4822, 2013.
19. Hoen B, Paul-Dauphin A, Kessler M: Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57: 457–461, 2002.
20. Official Journal of the International Scoiety of Nephrology: Kidney International Supplements. Available at: http://www.kdigo.org/clinical_practice:guidelines/pdf/KDIGO-Anemia%20GL.pdf. Accessed September 16, 2014.